Form 4 for CGEM Cullinan Therapeutics, Inc.
Accepted 2023-02-21 00:00:00 ET · period of report 2023-02-17 · accession 0000899243-23-005735 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-21 | 2023-02-17 | CGEM | Savill Corrine | Chief Business Off | A - Grant | $0.00 | +20.5K | 170.1K | +14% | $0 |
| D | 2023-02-21 | 2023-02-17 | CGEM | Savill Corrine | Chief Business Off | A - Grant | $0.00 | +41.0K | 41.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-17 | A | A | 20,500 | $0.00 | 170,115 | D | — | — | (F1) The shares underlying the restricted stock unit vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-02-17 | A | A | 41,000 | $0.00 | 41,000 | D | $11.34 · — to 2033-02-16 | 41,000 Common Stock | (F2) The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. |